Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Pablo Tebas, MD

Pablo Tebas, MD Physician

Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania Director, Developmental Core, Penn Center for AIDS Research Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Tebas is employed by Penn Medicine.

About Dr. Pablo Tebas

Recognized by Best Doctors in America 2007-2008, 2009-2010, 2011-2012

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Patient Comments

Clinical Specialties

Specialty:

  • Infectious Diseases

Programs & Centers:

Board Certification:

  • Infectious Disease, 2005
  • Internal Medicine, 2004

Description of Clinical Expertise

My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Universidad Autonoma De Madrid
Fellowship: Barnes-Jewish Hospital - Washington University, St. Louis

Memberships

American Society for Microbiology (ASM), National Department of Health and Human Services (DHHS) , National HIV Medical Association (HIVMA-IDSA), National Infectious Diseases Society of America (IDSA), National International AIDS Society, International International AIDS Society-USA, National NIH, Division of AIDS, AIDS Clinical Trial Group, National Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (Spanish Society of Infectious Diseases and Clinical Microbiology), National Sociedad Española de Medicina Interna (Spanish Society of Internal Medicine), National

Hospital Affiliation

Dr. Tebas is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Selected Publications:

Bedimo, R. J., Adams-Huet, B., Poindexter, J., Brown, G., Farukhi, I., Castanon, R., Turner, D., Moore, T., Tebas, P., Maalouf, N. M.: The Differential Effects of HIV and HCV on Bone Micro-Architecture and Fracture risk Clin Infect Dis : 2017.

George, V., Harrison, L., Roach, M., Li, X. D., Tierney, C., Fischl, M. A., Aberg, J., Tebas, P., Asmuth, D. M., Pollard, R. B., Godfrey, C., Pahwa, S., Aids Clinical Trials Group A Study Team: Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome J Infect Dis : 2017.

Tebas, P., Roberts, C. C., Muthumani, K., Reuschel, E. L., Kudchodkar, S. B., Zaidi, F. I., White, S., Khan, A. S., Racine, T., Choi, H., Boyer, J., Park, Y. K., Trottier, S., Remigio, C., Krieger, D., Spruill, S. E., Bagarazzi, M., Kobinger, G. P., Weiner, D. B., Maslow, J. N.: Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report N Engl J Med : 2017.

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E: Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial Lancet 36 (17): 32299-7,2017.

Kelly, B. J., Tebas, P.: Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection Chest : 2017.

Herati RS, Muselman A, Vella L, Bengsch B, Parkhouse K, Del Alcazar D, Kotzin J, Doyle SA, Tebas P, Hensley SE, Su LF, Schmader KE, Wherry EJ: Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells Sci Immunol 2 (8): 2017.

Yin, M. T., Chan, E. S., Brown, T. T., Tebas, P., McComsey, G. A., Melbourne, K., Napoli, A., Hardin, R., Ribaudo, H. J., Overton, E. T., A. Study Team: Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation: ACTG A5280 AIDS : 2017.

Koenig HC, Mounzer K, Daughtridge GW, Sloan CE, Lalley-Chareczko L, Moorthy GS, Conyngham SC, Zuppa AF, Montaner LJ, Tebas P: Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis HIV Med 18 (6): 412-418,2017.

Beigel, J. H., Tebas, P., Elie-Turenne, M. C., Bajwa, E., Bell, T. E., Cairns, C. B., Shoham, S., Deville, J. G., Feucht, E., Feinberg, J., Luke, T., Raviprakash, K., Danko, J., O'Neil, D., Metcalf, J. A., King, K., Burgess, T. H., Aga, E., Lane, H. C., Hughes, M. D., Davey, R. T., I. R. C. Study Team: Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study Lancet Respir Med 5 (6): 500-511,2017.

Drechsler, H., Ayers, C., Cutrell, J., Maalouf, N., Tebas, P., Bedimo, R.: Current use of statins reduces risk of HIV rebound on suppressive HAART PLoS One 12 (3): e0172175,2017.

Academic Contact Info

Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 349-8092
Patient appointments: 800-789-7366 (PENN)

Related Links